421 related articles for article (PubMed ID: 24650055)
1. The efficacy of generic formulations of imatinib mesylate in the treatment of chronic myeloid leukemia.
Eskazan AE; Elverdi T; Yalniz FF; Salihoglu A; Ar MC; Ongoren Aydin S; Baslar Z; Aydin Y; Tuzuner N; Ozbek U; Soysal T
Leuk Lymphoma; 2014 Dec; 55(12):2935-7. PubMed ID: 24650055
[No Abstract] [Full Text] [Related]
2. Generics in chronic myeloid leukemia: current arguments for and against and the established evidence.
Soysal T; Eskazan AE; Ar MC
Expert Rev Hematol; 2014 Dec; 7(6):697-9. PubMed ID: 25292262
[TBL] [Abstract][Full Text] [Related]
3. Imatinib for chronic myeloid leukaemia: a NICE mess.
Rajaratnam G; Edwards J
Lancet; 2001 Dec; 358(9296):1902. PubMed ID: 11741655
[No Abstract] [Full Text] [Related]
4. Targeted cancer therapy: from bench to bedside to patient.
Gellad WF
J Clin Oncol; 2014 Feb; 32(4):268-70. PubMed ID: 24366939
[No Abstract] [Full Text] [Related]
5. Imatinib for chronic myeloid leukaemia: a NICE mess.
Barbour V
Lancet; 2001 Nov; 358(9292):1478. PubMed ID: 11705557
[No Abstract] [Full Text] [Related]
6. Pharmacoeconomic benefits of dasatinib in the treatment of imatinib-resistant patients with chronic myelogenous leukemia.
Taylor MJ; Scuffham PA
Expert Rev Pharmacoecon Outcomes Res; 2009 Apr; 9(2):117-21. PubMed ID: 19402798
[TBL] [Abstract][Full Text] [Related]
7. Changing the cost of care for chronic myeloid leukemia: the availability of generic imatinib in the USA and the EU.
Conti RM; Padula WV; Larson RA
Ann Hematol; 2015 Apr; 94 Suppl 2(0 2):S249-57. PubMed ID: 25814091
[TBL] [Abstract][Full Text] [Related]
8. Imatinib for chronic myeloid leukaemia: a NICE mess.
O'Brien SG
Lancet; 2001 Dec; 358(9296):1902-3. PubMed ID: 11741654
[No Abstract] [Full Text] [Related]
9. Perspective: combined forces.
Sawyers CL
Nature; 2013 Jun; 498(7455):S7. PubMed ID: 23803949
[No Abstract] [Full Text] [Related]
10. Effectiveness of imatinib therapy for sickle cell anemia and chronic myeloid leukemia.
Murphy M; Close J; Lottenberg R; Rajasekhar A
Am J Med Sci; 2014 Mar; 347(3):254-5. PubMed ID: 24553361
[No Abstract] [Full Text] [Related]
11. Position paper on imatinib mesylate in chronic myeloid leukaemia.
O'Brien SG; Rule SA
Br J Haematol; 2002 Oct; 119(1):268-72. PubMed ID: 12358935
[No Abstract] [Full Text] [Related]
12. Application of comorbidity indexes at baseline could be useful to predict rates of response in patients with chronic myeloid leukemia treated with imatinib.
Breccia M; Salaroli A; Serrao A; Zacheo I; Saracino R; Alimena G
Leuk Lymphoma; 2014 Jan; 55(1):204-6. PubMed ID: 23586870
[No Abstract] [Full Text] [Related]
13. The effectiveness and cost-effectiveness of imatinib in chronic myeloid leukaemia: a systematic review.
Garside R; Round A; Dalziel K; Stein K; Royle P
Health Technol Assess; 2002; 6(33):1-162. PubMed ID: 12633529
[No Abstract] [Full Text] [Related]
14. Cost-effectiveness of nilotinib, dasatinib and imatinib as first-line treatment for chronic myeloid leukemia in Colombia, 2012.
Romero M; Chávez D; De Los Ríos M; Alvis-Guzmán N
Biomedica; 2014; 34(1):48-59. PubMed ID: 24968906
[TBL] [Abstract][Full Text] [Related]
15. Delayed initiation of front-line imatinib therapy predicts for poor response to nilotinib as second-line treatment of imatinib-resistant or intolerant CML: single center report of the ENACT trial in Lebanon.
Otrock ZK; Mahfouz RA; Fahed Z; Farhat FS; Ziade A; Nasr F; Kassem N; Abboud MR
Int J Hematol; 2012 Oct; 96(4):521-4. PubMed ID: 22961257
[No Abstract] [Full Text] [Related]
16. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia.
Dusetzina SB; Winn AN; Abel GA; Huskamp HA; Keating NL
J Clin Oncol; 2014 Feb; 32(4):306-11. PubMed ID: 24366936
[TBL] [Abstract][Full Text] [Related]
17. Pregnancy outcomes in patients with chronic myeloid leukemia treated with imatinib mesylate: short report from a developing country.
Iqbal J; Ali Z; Khan AU; Aziz Z
Leuk Lymphoma; 2014 Sep; 55(9):2109-13. PubMed ID: 24237577
[TBL] [Abstract][Full Text] [Related]
18. Drug developers unveil strategies aimed at imatinib-resistant CML.
Goozner M
J Natl Cancer Inst; 2010 May; 102(9):593-5. PubMed ID: 20421566
[No Abstract] [Full Text] [Related]
19. New directions in the treatment of patients with chronic myeloid leukemia: introduction.
Baccarani M
Semin Hematol; 2009 Apr; 46(2 Suppl 3):S1-4. PubMed ID: 19621542
[No Abstract] [Full Text] [Related]
20. [Chronic myeloid leukemia 2008].
Cervantes F
Med Clin (Barc); 2008 Nov; 131(17):658-9. PubMed ID: 19087793
[No Abstract] [Full Text] [Related]
[Next] [New Search]
